The field of clinical behavior analysis is growing rapidly and has the potential to affect and transform mainstream cognitive behavior therapy. To have such an impact, the field must provide a formulation of and intervention strategies for clinical depression, the "common cold" of outpatient populations. Two treatments for depression have emerged: acceptance and commitment therapy (ACT) and behavioral activation (BA). At times ACT and BA may suggest largely redundant intervention strategies. However, at other times the two treatments differ dramatically and may present opposing conceptualizations. This paper will compare and contrast these two important treatment approaches. Then, the relevant data will be presented and discussed. We will end with some thoughts on how and when ACT or BA should be employed clinically in the treatment of depression.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2223147 | PMC |
| http://dx.doi.org/10.1007/BF03392129 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Protocol to assess bottlenecks inhibiting the scaling up of evidence-based family planning practices in low-income and middle-income countries using mixed methods.
BMJ Open
December 2024
Department of Sexual and Reproductive Health and Research including UNDP/UNFPA/UNICEF/WHO/World Bank Special Programme of Research, World Health Organization, Geneva, Switzerland.
Introduction: Scaling up evidence-based practices (EBPs) in family planning (FP), as recommended by the WHO, has increasingly been accepted by global health actors as core to their mission, goals and activities. National policies, strategies, guidance, training materials, political commitment and donor support exist in many countries to adopt and scale up a range of EBPs, including postpregnancy FP, task sharing for FP and the promotion of social and behaviour change (SBC) for FP. While there has been some success in implementing these practices, coverage remains inadequate in many countries.
View Article and Find Full Text PDFA systematic review on how to combine exposure and response prevention with add-ons for the treatment of obsessive-compulsive disorder.
Psychotherapy (Chic)
January 2025
Psychology Research Center, Psychotherapy and Psychopathology Research Unit, School of Psychology, University of Minho.
Exposure and response prevention (ERP) is an effective treatment for obsessive-compulsive disorder. However, ERP's distressful nature may be too demanding for some patients, resulting in low engagement with treatment or even dropout. The current review aimed to summarize and categorize the components of ERP plus add-on protocols.
View Article and Find Full Text PDFOrganizational factors impacting the implementation of a digital mental health tool in Alberta's mental health care of youth and young adults.
Digit Health
January 2025
Faculty of Social Work, Mathison Centre for Mental Health Education and Research, University of Calgary, Calgary, Alberta, Canada.
With mental health concerns on the rise among youth and young adults (age 12-24), increased mental health options include virtual care, apps and online tools, self-management and tracking tools, and digitally-enabled coordination of care. These tools may function as alternatives or adjuncts to face-to-face models of care. Innovative solutions in the form of digital mental health (dMH) services not only provide support, resources and care, but also decrease wait times and waitlists, increase access, and empower youth.
View Article and Find Full Text PDFHigh Prevalence of Burnout in Veterinary Medicine: Exploring Interventions to Improve Well-being.
Vet J
January 2025
Faculty of Data Science, Musashino University, 3-3-3 Ariake Koto-ku, Tokyo 135-8181, Japan. Electronic address:
The veterinary profession faces a critical challenge: burnout. Long hours, emotional strain, financial pressures, and difficult client interactions contribute to stress and drive veterinary professionals from the field. This harms not only their well-being but also patient care and workplace morale.
View Article and Find Full Text PDFRepurposing Licensed Drugs with Activity Against Epstein-Barr Virus for Treatment of Multiple Sclerosis: A Systematic Approach.
CNS Drugs
January 2025
School of Medicine and Dentistry, Gold Coast Campus, Griffith University, Southport, QLD, 4222, Australia.
Background: Epstein-Barr virus (EBV) is implicated as a necessary factor in the development of multiple sclerosis (MS) and may also be a driver of disease activity. Although it is not clear whether ongoing viral replication is the driver for MS pathology, MS researchers have considered the prospect of using drugs with potential efficacy against EBV in the treatment of MS. We have undertaken scientific and lived experience expert panel reviews to shortlist existing licensed therapies that could be used in later-stage clinical trials in MS.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!